Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway

John Seubert, Baichun Yang, J. Alyce Bradbury, Joan Graves, Laura M. Degraff, Scott Gabel, Rebecca Gooch, Julie Foley, John Newman, Lan Mao, Howard A. Rockman, Bruce D. Hammock, Elizabeth Murphy, Darryl C. Zeldin

Research output: Contribution to journalArticle

210 Citations (Scopus)

Abstract

Human CYP2J2 is abundant in heart and active in the biosynthesis of epoxyeicosatrienoic acids (EETs); however, the functional role of this P450 and its eicosanoid products in the heart remains unknown. Transgenic mice with cardiomyocyte-specific overexpression of CYP2J2 were generated. CYP2J2 transgenic (Tr) mice have normal heart anatomy and basal contractile function. CYP2J2 Tr hearts have improved recovery of left ventricular developed pressure (LVDP) compared with wild-type (WT) hearts after 20 minutes ischemia and 40 minutes reperfusion. Perfusion with the selective P450 epoxygenase inhibitor N-methylsulphonyl-6-(2-proparglyloxyphenyl)hexanamide (MS-PPOH) for 20 minutes before ischemia results in reduced postischemic LVDP recovery in WT hearts and abolishes the improved postischemic LVDP recovery in CYP2J2 Tr hearts. Perfusion with the ATP-sensitive K+ channel (KATP) inhibitor glibenclamide (GLIB) or the mitochondrial KATP (mitoKATP) inhibitor 5-hydroxydecanoate (5-HD) for 20 minutes before ischemia abolishes the cardioprotective effects of CYP2J2 overexpression. Flavoprotein fluorescence, a marker of mitoKATP, activity, is higher in cardiomyocytes from CYP2J2 Tr versus WT mice. Moreover, CYP2J2-derived EETs (1 to 5 μmol/L) increase flavoprotein fluorescence in WT cardiomyocytes. CYP2J2 Tr mice exhibit increased expression of phospho-p42/p44 mitogen-activated protein kinase (MAPK) after ischemia, and addition of the p42/p44 MAPK kinase (MEK) inhibitor PD98059 during reperfusion abolishes the cardioprotective effects of CYP2J2 overexpression. Together, these data suggest that CYP2J2-derived metabolites are cardioprotective after ischemia, and the mechanism for this cardioprotection involves activation of mitoKATP and p42/p44 MAPK.

Original languageEnglish (US)
Pages (from-to)506-514
Number of pages9
JournalCirculation Research
Volume95
Issue number5
DOIs
StatePublished - Sep 3 2004

Fingerprint

Mitogen-Activated Protein Kinase 1
Ischemia
Ventricular Pressure
Cardiac Myocytes
Transgenic Mice
Flavoproteins
Mitogen-Activated Protein Kinase Kinases
Reperfusion
arachidonate epoxygenase
mitochondrial K(ATP) channel
Perfusion
Fluorescence
KATP Channels
Eicosanoids
Glyburide
Anatomy
Adenosine Triphosphate

Keywords

  • Arachidonic acid
  • Cytochrome P450
  • Eicosanoid
  • Ischemia/reperfusion
  • MAPK
  • MitoK channel

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. / Seubert, John; Yang, Baichun; Bradbury, J. Alyce; Graves, Joan; Degraff, Laura M.; Gabel, Scott; Gooch, Rebecca; Foley, Julie; Newman, John; Mao, Lan; Rockman, Howard A.; Hammock, Bruce D.; Murphy, Elizabeth; Zeldin, Darryl C.

In: Circulation Research, Vol. 95, No. 5, 03.09.2004, p. 506-514.

Research output: Contribution to journalArticle

Seubert, J, Yang, B, Bradbury, JA, Graves, J, Degraff, LM, Gabel, S, Gooch, R, Foley, J, Newman, J, Mao, L, Rockman, HA, Hammock, BD, Murphy, E & Zeldin, DC 2004, 'Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway', Circulation Research, vol. 95, no. 5, pp. 506-514. https://doi.org/10.1161/01.RES.0000139436.89654.c8
Seubert, John ; Yang, Baichun ; Bradbury, J. Alyce ; Graves, Joan ; Degraff, Laura M. ; Gabel, Scott ; Gooch, Rebecca ; Foley, Julie ; Newman, John ; Mao, Lan ; Rockman, Howard A. ; Hammock, Bruce D. ; Murphy, Elizabeth ; Zeldin, Darryl C. / Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. In: Circulation Research. 2004 ; Vol. 95, No. 5. pp. 506-514.
@article{1602a0d7444c4f0181fa92d466c26efa,
title = "Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway",
abstract = "Human CYP2J2 is abundant in heart and active in the biosynthesis of epoxyeicosatrienoic acids (EETs); however, the functional role of this P450 and its eicosanoid products in the heart remains unknown. Transgenic mice with cardiomyocyte-specific overexpression of CYP2J2 were generated. CYP2J2 transgenic (Tr) mice have normal heart anatomy and basal contractile function. CYP2J2 Tr hearts have improved recovery of left ventricular developed pressure (LVDP) compared with wild-type (WT) hearts after 20 minutes ischemia and 40 minutes reperfusion. Perfusion with the selective P450 epoxygenase inhibitor N-methylsulphonyl-6-(2-proparglyloxyphenyl)hexanamide (MS-PPOH) for 20 minutes before ischemia results in reduced postischemic LVDP recovery in WT hearts and abolishes the improved postischemic LVDP recovery in CYP2J2 Tr hearts. Perfusion with the ATP-sensitive K+ channel (KATP) inhibitor glibenclamide (GLIB) or the mitochondrial KATP (mitoKATP) inhibitor 5-hydroxydecanoate (5-HD) for 20 minutes before ischemia abolishes the cardioprotective effects of CYP2J2 overexpression. Flavoprotein fluorescence, a marker of mitoKATP, activity, is higher in cardiomyocytes from CYP2J2 Tr versus WT mice. Moreover, CYP2J2-derived EETs (1 to 5 μmol/L) increase flavoprotein fluorescence in WT cardiomyocytes. CYP2J2 Tr mice exhibit increased expression of phospho-p42/p44 mitogen-activated protein kinase (MAPK) after ischemia, and addition of the p42/p44 MAPK kinase (MEK) inhibitor PD98059 during reperfusion abolishes the cardioprotective effects of CYP2J2 overexpression. Together, these data suggest that CYP2J2-derived metabolites are cardioprotective after ischemia, and the mechanism for this cardioprotection involves activation of mitoKATP and p42/p44 MAPK.",
keywords = "Arachidonic acid, Cytochrome P450, Eicosanoid, Ischemia/reperfusion, MAPK, MitoK channel",
author = "John Seubert and Baichun Yang and Bradbury, {J. Alyce} and Joan Graves and Degraff, {Laura M.} and Scott Gabel and Rebecca Gooch and Julie Foley and John Newman and Lan Mao and Rockman, {Howard A.} and Hammock, {Bruce D.} and Elizabeth Murphy and Zeldin, {Darryl C.}",
year = "2004",
month = "9",
day = "3",
doi = "10.1161/01.RES.0000139436.89654.c8",
language = "English (US)",
volume = "95",
pages = "506--514",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway

AU - Seubert, John

AU - Yang, Baichun

AU - Bradbury, J. Alyce

AU - Graves, Joan

AU - Degraff, Laura M.

AU - Gabel, Scott

AU - Gooch, Rebecca

AU - Foley, Julie

AU - Newman, John

AU - Mao, Lan

AU - Rockman, Howard A.

AU - Hammock, Bruce D.

AU - Murphy, Elizabeth

AU - Zeldin, Darryl C.

PY - 2004/9/3

Y1 - 2004/9/3

N2 - Human CYP2J2 is abundant in heart and active in the biosynthesis of epoxyeicosatrienoic acids (EETs); however, the functional role of this P450 and its eicosanoid products in the heart remains unknown. Transgenic mice with cardiomyocyte-specific overexpression of CYP2J2 were generated. CYP2J2 transgenic (Tr) mice have normal heart anatomy and basal contractile function. CYP2J2 Tr hearts have improved recovery of left ventricular developed pressure (LVDP) compared with wild-type (WT) hearts after 20 minutes ischemia and 40 minutes reperfusion. Perfusion with the selective P450 epoxygenase inhibitor N-methylsulphonyl-6-(2-proparglyloxyphenyl)hexanamide (MS-PPOH) for 20 minutes before ischemia results in reduced postischemic LVDP recovery in WT hearts and abolishes the improved postischemic LVDP recovery in CYP2J2 Tr hearts. Perfusion with the ATP-sensitive K+ channel (KATP) inhibitor glibenclamide (GLIB) or the mitochondrial KATP (mitoKATP) inhibitor 5-hydroxydecanoate (5-HD) for 20 minutes before ischemia abolishes the cardioprotective effects of CYP2J2 overexpression. Flavoprotein fluorescence, a marker of mitoKATP, activity, is higher in cardiomyocytes from CYP2J2 Tr versus WT mice. Moreover, CYP2J2-derived EETs (1 to 5 μmol/L) increase flavoprotein fluorescence in WT cardiomyocytes. CYP2J2 Tr mice exhibit increased expression of phospho-p42/p44 mitogen-activated protein kinase (MAPK) after ischemia, and addition of the p42/p44 MAPK kinase (MEK) inhibitor PD98059 during reperfusion abolishes the cardioprotective effects of CYP2J2 overexpression. Together, these data suggest that CYP2J2-derived metabolites are cardioprotective after ischemia, and the mechanism for this cardioprotection involves activation of mitoKATP and p42/p44 MAPK.

AB - Human CYP2J2 is abundant in heart and active in the biosynthesis of epoxyeicosatrienoic acids (EETs); however, the functional role of this P450 and its eicosanoid products in the heart remains unknown. Transgenic mice with cardiomyocyte-specific overexpression of CYP2J2 were generated. CYP2J2 transgenic (Tr) mice have normal heart anatomy and basal contractile function. CYP2J2 Tr hearts have improved recovery of left ventricular developed pressure (LVDP) compared with wild-type (WT) hearts after 20 minutes ischemia and 40 minutes reperfusion. Perfusion with the selective P450 epoxygenase inhibitor N-methylsulphonyl-6-(2-proparglyloxyphenyl)hexanamide (MS-PPOH) for 20 minutes before ischemia results in reduced postischemic LVDP recovery in WT hearts and abolishes the improved postischemic LVDP recovery in CYP2J2 Tr hearts. Perfusion with the ATP-sensitive K+ channel (KATP) inhibitor glibenclamide (GLIB) or the mitochondrial KATP (mitoKATP) inhibitor 5-hydroxydecanoate (5-HD) for 20 minutes before ischemia abolishes the cardioprotective effects of CYP2J2 overexpression. Flavoprotein fluorescence, a marker of mitoKATP, activity, is higher in cardiomyocytes from CYP2J2 Tr versus WT mice. Moreover, CYP2J2-derived EETs (1 to 5 μmol/L) increase flavoprotein fluorescence in WT cardiomyocytes. CYP2J2 Tr mice exhibit increased expression of phospho-p42/p44 mitogen-activated protein kinase (MAPK) after ischemia, and addition of the p42/p44 MAPK kinase (MEK) inhibitor PD98059 during reperfusion abolishes the cardioprotective effects of CYP2J2 overexpression. Together, these data suggest that CYP2J2-derived metabolites are cardioprotective after ischemia, and the mechanism for this cardioprotection involves activation of mitoKATP and p42/p44 MAPK.

KW - Arachidonic acid

KW - Cytochrome P450

KW - Eicosanoid

KW - Ischemia/reperfusion

KW - MAPK

KW - MitoK channel

UR - http://www.scopus.com/inward/record.url?scp=4444236138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444236138&partnerID=8YFLogxK

U2 - 10.1161/01.RES.0000139436.89654.c8

DO - 10.1161/01.RES.0000139436.89654.c8

M3 - Article

VL - 95

SP - 506

EP - 514

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 5

ER -